

An overview of keratitis, Etiology, and management approaches

Zainab Hassan Muhammad Alhakami , Afnan Mohammad Ali Madkhali

Abstract:

This review tries to provide current information on most, though not all, aspects of keratitis like etiology, diagnosis and management types. We searched in the PubMed and EMBASE for articles related to the search strategy "(Etiology) AND (bacterial eye infection OR keratitis OR microbial keratitis OR bacterial keratitis)", from the start date of the databases to July, 2018. Management of keratitis continues to be a significant challenge worldwide, more so in low- and also middle-income nations with inadequate healthcare sources. Although the outcome of therapy has improved substantially, several patients remain to degrade despite the very best treatment that can be used. The ongoing emergence of strains of microbes that are resistant to an ever-expanding variety of antimicrobials presents an added obstacle. Further study pertaining to prevention of microbial keratitis and improving host resistance are 2 worthwhile goals to go after. Large-scale public education programs to alert those in danger of microbial keratitis, and also to motivate earlier discussion, ought to be undertaken.

Introduction:

Corneal disease remains the leading cause of monocular blindness worldwide, especially affecting marginalized populations[1]. Corneal opacities, which are largely caused by infectious keratitis, are the fourth leading cause of blindness globally and are responsible for 10% of avoidable visual impairment in the world's least developed countries [2,3] Infections of the cornea can lead to corneal opacity and blindness if not identified quickly and managed appropriately. The terms 'microbial keratitis', 'infective keratitis' and 'suppurative keratitis' are all used to describe suppurative infections of the cornea. Approximately 2 million people develop a corneal ulcer every year in India alone [4,5] In the United States, infectious keratitis often is associated with contact lens wear,[6-8]but in developing countries it is more commonly caused by ocular trauma sustained during agricultural work [9-12].The common symptomatic complaints of patients with microbial keratitis are as follows (all with varying degrees of severity):redness of the eye ,pain, blurring of vision, photophobia ,watering or discharge from the eye[2-5].

Keratitis or corneal inflammation is a major reason of ocular morbidity around the world. Fortunately, the majority of the situations are successfully managed with medical therapy, but the failure of therapy does occur, leading to devastating consequences of either losing the vision or the eye. This review tries to provide current information on most, though not all, aspects of keratitis like etiology, diagnosis and management types.

Methodology:

We searched in the PubMed and EMBASE for articles related to the search strategy

"(Etiology) AND (bacterial eye infection OR keratitis OR microbial keratitis OR bacterial keratitis)", from the start date of the databases to July, 2018. We then searched references

lists of included articles for more relevant studies. Finally, we restricted our search to only English with human subject studies.

Discussion:

- **Etiology**

Apart from being an important element of the refractive system of the eye the cornea offers to protect the much more delicate structure of the anterior sector of the eye from injury. A selection of illness might cause either certain or nonspecific changes in corneal tissues including inflammation or keratitis. The majority of inflammations are characterized by nonspecific local or scattered edema, which is manifested clinically by lack of corneal transparency [10-12]. The preliminary vascular reaction to corneal inflammation is perilimbal hyperemia, which may expand around the whole periphery or entail only one segment. Corneal inflammatory cells are stemmed from the shallow and deep limbal vessels. The leukocytes migrate toward the site of the launching inflammatory stimulus, complying with interlamellar pathways and also creating abnormalities in the structural placement of the lamellae.

The initial cellular migration includes interlamellar polymorphonuclear leukocytes that show up within 8 to 12 hr after injury [13]. During the adhering to 12 to 16 hours, migrating macrophages (phagocytes) occurring from the limbus, in addition to tissue macrophages originated from stromal cells, begin to consume bacteria and inflammatory products. Speculative evidence recommends that antigen related to macrophages may be a crucial way to start stimulation of lymphocytic components and also specific immune reactions. During the healing response to swelling, neovascularization of cornea prevails which happens in response to a number of factors

such as, edema, cellular infiltration, tissue death, adjustments in pH, oxidative procedures, enzymes from inflammatory cells and corneal tissue cells, and so on. The extent of vascularization varies with the severity and size of the inflammatory focus and also with its period. Pain is typically present with corneal swelling as a result of excitement of the sensory ciliary branches of the ophthalmic division of the trigeminal nerve. Swellings that lower corneal sensation, such as herpes simplex keratitis, could be less painful in first phases [10-13].

Corneal swelling could be ulcerative (breach in corneal epithelium with underlying infiltration of inflammatory cells) or nonulcerative [13]. Etiologically, either of these may be infectious or non-infectious. While comprehensive description of the scientific as well as laboratory findings related to all infectious and also noninfectious forms of ketatitis is past the extent of this review, a big picture of numerous of these entities is given.

Nonulcerative stromal keratitis or interstitial keratitis occurs when conjunctival as well as shallow corneal infections reach the stroma, or there is an immune reaction within the stroma. Stromal inflammation might likewise accompany systemic conditions such as, syphilis and consumption. There can be several causes of interstitial keratitis (Table 1). The primary inflammatory stimulation may originate within the stroma, or it may arise at the limbus or uveal system as well as spread to the stroma. Characteristically, the epithelium stays intact while the involved stroma becomes edematous. In serious instances, folds up develop in Descemet's membrane layer. Edema as well as cellular seepage triggering a diluted stromal haze is referred to as "disciform" keratitis when it occupies the central portion of the cornea. Several problems could create "disciform keratitis", nevertheless, Herpes simplex keratitis is one of the most common reason.

Table 1. Causes of Nonulcerative Stromal (Interstitial) Keratitis [14-23].

Bacterial infection	Viral infection
---------------------	-----------------

Syphilis Tuberculosis Leprosy Lyme disease Brucellosis	Herpes simplex virus Varicella zoster virus Epstein–Barr virus Mumps Rubella
Parasitic infection Leishmaniasis Onchocerciasis Trypanosomiasis Acanthamoeba Microsporidiosis	Systemic disease Cogan's syndrome Sarcoidosis Lymphoma

Ulcerative keratitis could be produced by infectious organisms (microbial keratitis) or by noninfectious stimuli [25]. During the preliminary phases, the epithelium and also the stroma in the location of injury or stimulations become edematous as well as undertake death. Acute as well as chronic inflammatory cells infiltrate from the limbus. As the process progresses, a deep stromal abscess could develop under the ulcer. Diffusion of inflammatory conciliators posteriorly could generate a cascade of inflammatory cells in the former chamber (hypopyon)[24-28]. If the inflammation is serious, the superficial abscess and the deep abscess could fulfill, with resultant sloughing of the infected stroma. The remaining cornea including a couple of posterior lamellae of stroma and also Descemet's membrane, may after that bulge onward (descemetocele) or become necrotic and rupture, giving rise to perforated corneal ulcer. As the sore begins to heal, epithelium migrates right into the crater of the ulcer from the sides. Vessels originated from the limbus and also fibroblasts derived from the stroma grow into the area under the epithelium. Macrophages aid in improving the debris, and also a connective tissue scar starts to develop [31]. The scar is generally discovered to discontinue its development at the level of the bordering regular cornea. Later on hyaline, calcareous, or lipid degeneration of the mark may occur. Virtually any type of bacteria could possibly trigger keratitis (Table 2).

Table 2. Classification of Bacteria Causing Keratitis [24-32]

<i>Gram-negative</i>	<i>Actinomycetes and related</i>	<i>Gram-positive aerobic and/or</i>
----------------------	----------------------------------	-------------------------------------

aerobic/facultative rods Pseudomonas Asotobacter Escherichia Citrobacter Klebsiella Serratia Proteus Actinobacillus Flaûobacterium Haemophilus	anaerobic organisms Corynebacterium Porpionibacterium Actinomyces Arachnia Bifidobacterium Mycobacterium Nocardia Streptomyces	facultatively anaerobic cocci Micrococcus Staphylococcus Streptococcus Pediococcus Aerococcus
Gram-positive anaerobic cocci Peptostreptococcus Gram-positiûe rods Bacillus Clostridium	Gram-negative anaerobic rods Bacteroides Fusobacterium	Gram-negative cocci and coccobacilli (aerobes) Neisseria Moraxella Acinetobacter

Fungal Keratitis. *Fungi* are common, saprophytic and periodically a part of the normal external ocular flora (Table 3). They gain access right into the corneal stroma with an issue in epithelial barrier which could result from exterior trauma, an endangered ocular surface area, or previous surgical procedure. Once in the stroma, they multiply and also cause tissue necrosis and also a host inflammatory reaction. Microorganisms could penetrate deep right into the stroma as well as via an undamaged Descemet's membrane. It is believed that as soon as the microorganisms get into the anterior chamber or to the iris and lens, obliteration of the microorganism comes to be very difficult.

Table 3. Etiological Agents in Mycotic Keratitis [42-46]

<i>Hyaline filamentous fungi</i> Aspergillus spp Acremonium spp Beauûeria spp Cylindrocarpon spp Fusarium spp Geotrichum candidum Neurospora spp Penicillium spp Paecilomyces spp Pseudallescheria boydii Sphaeropsis subglobosa Scopulariopsis	<i>Dematiaceous filamentous fungi</i> Alternaria spp Bipolaris spp Curûularia spp Cladosporium spp Drechslera spp Exserophilum spp Exophiala jeanselmei Lasiodiplodia theobromae Phialophora spp
--	--

Ustilago spp Volutella spp	
Yeasts and yeast—like fungi Candida spp Cryptococcus spp Rhodotorula spp Trichosporon spp	Dimorphic fungi Blastomyces dermatitidis Paracoccidoides brasiliensis Sporothrix schenckii

• **Diagnosis**

Appropriate medical diagnosis of keratitis is important to figuring out therapy as well as attaining resolution of infection. The mainstay in diagnosis is still Gram stain and culture of corneal samples despite incomplete level of sensitivity [33-35]. Gram and also Giemsa spots are beneficial since they supply instant results, with Gram stain precisely discovering the original organism 60% to 75% of the time in microbial cases and 35% to 90% in fungal cases. Giemsa has a sensitivity of 40% to 85% for detecting fungal situations [36-38]. Blood and also chocolate agar are most commonly used to society germs, whereas Sabouraud's agar or potato dextrose are best for isolating fungus, and also non-nutrient agar with Escherichia coli overlay can be made use of to culture Acanthamoeba. Thioglycollate broth is an additional choice to identify aerobic or facultatively anaerobic microorganisms, yet contamination is a trouble, and frequently it is difficult to identify whether separated organisms are the root cause of infection [39]. Viral keratitis is detected greatly on clinical exam as a result of its characteristic dendritic look, [40] however polymerase chain reaction is occasionally used to confirm medical diagnosis with high sensitivity [41]. There is still substantial space for exploration of unique methods of identifying infectious keratitis. In vivo confocal microscopy has grown in popularity in recent years because of its rapidity as well as high sensitivity in discovering larger microorganisms, such as filamentous fungus, acanthamoeba, and Nocardia germs (Fig 1) [42-46]. Anterior segment optical

coherence tomography has been used a lot more recently to supply an unbiased measure of corneal infiltrate or scar dimension or to monitor corneal thinning throughout therapy [47],[48].




Figure 1. Confocal microscopy image from a patient with filamentous fungal keratitis

- **Management of Keratitis**

Bacterial keratitis is most related to get in touch with lens usage [39]. Extreme cases could progress quickly and also trigger permanent vision loss requiring corneal replacement.

Topical antibiotics continue to be the first-line treatment for bacterial keratitis. Clinicians evaluate numerous factors when picking an antibiotic routine, consisting of broad-spectrum insurance coverage, toxicity, accessibility and also price, and also regionspecific epidemiology of virus as well as resistance patterns. Indeed, a current worldwide survey of cornea specialists located that problems over several of these factors were predictive of antibiotic choice [49]. A current Cochrane-style review of high-quality, randomized, controlled, medical trials on the management of bacterial keratitis with topical prescription antibiotics identified 16 trials contrasting 2 or more topical prescription antibiotics over at least 7 days. McDonald et alia [50] discovered no significant difference in the family member threat of treatment success specified as

complete re-epithelialization of the cornea or promptly to cure. Although there was a rise in the related danger of small damaging occasions, such as eye discomfort or chemical conjunctivitis with aminoglycoside-cephalosporin compared to fluoroquinolones, there was no difference in major complications [51-53].

Using adjuvant corticosteroids has long been debated in the therapy of microbial keratitis [54-56]. Proponents of using corticosteroids say that they improve outcomes by decreasing swelling, consequently lowering scarring, neovascularization, and stromal thaw [57-60]. Nonetheless, others say that corticosteroids postpone epithelial recovery as well as may also intensify infection [60-63]. A current Cochrane testimonial of adjuvant topical steroids for bacterial keratitis determined 4 randomized regulated tests comparing adjuvant steroids with topical prescription antibiotics alone [64]. Three little randomized controlled tests checking out the advantage of adjuvant topical steroids for the therapy of corneal ulcers located no distinction in visual acuity end results or healing times in between those randomized to topical antibiotic alone and also those randomized to topical antibiotic plus topical steroid [65-67].

Fungal Keratitis Fungal ulcers usually have even worse end results compared to bacterial ulcers, as well as there is little proof to guide therapy [68]. Fungal keratitis stands for a reasonably small percent of transmittable keratitis cases in regions with temperate climates; nonetheless, in tropical environments it could cause as much as 50% of infectious ulcers [68].

Reliable treatment with topical natamycin 5% is limited by its inadequate infiltration right into the corneal stroma [69]. Topical amphotericin B 0.3% to 0.5% is an option, however its use requires access to an intensifying pharmacy as well as is limited by poisoning. Voriconazole, a newer-generation triazole, has gotten appeal in the therapy of fungal keratitis due to its outstanding eye infiltration [70]. Furthermore, in an in vitro research by Walsh et alia, [71]

voriconazole was the only medicine examined where 100% of fungal isolates commonly implicated in keratitis were prone.

Although topical voriconazole failed to show enhanced end results compared to natamycin, there are numerous reasons that oral voriconazole may have efficacy in the therapy of fungal keratitis. Initially, recurring application of topical medications might lead to periods of subtherapeutic drug degrees, and oral drugs could supply even more steady-state medicine levels at the site of infection. One research contrasting aqueous examples after topical and also oral voriconazole found that topical administration of voriconazole resulted in extremely variable liquid concentrations with troughs well below the minimum inhibitory focus at which 90% of fungal isolates are inhibited (MIC90). On the other hand, oral voriconazole offered healing medicine degrees that remained reasonably consistent [72]. Of note, in many case records of effective therapy with topical voriconazole, oral or intravenous voriconazole was utilized together with the topical medicine [73].

Viral Keratitis Herpes simplex virus (HSV) keratitis impacts an approximated 500 000 individuals in the United States and an approximated 1.5 million around the world [74]. It is the most usual reason for independent contagious corneal blindness in much of the developed globe. Viral keratitis differs from bacterial and also fungal keratitis because it can come to be chronic as well as recurrent. Besides being an unpleasant, sight-threatening infection, HSV keratitis has actually been revealed to substantially impact lifestyle even when patients are not experiencing an energetic infection [75]. Less usual kinds of viral keratitis include varicella-zoster virus (VZV) keratitis and also cytomegalovirus (CMV) keratitis. Topical Treatments Topical therapies for viral keratitis consist of antiviral medications as well as adjuvant topical corticosteroids. The topical antiviral trifluridine is the most commonly prescribed topical antiviral drug for HSV keratitis in the United States [76]. Although trifluridine is effective in dealing with

HSV keratitis, it has low bioavailability as well as triggers eye surface area toxicity, so its use has actually become more minimal as more recent topical antivirals are established [77]. Topical acyclovir is the first-line therapy for HSV keratitis in Europe because it has been shown to be just as effective as trifluridine with less ocular surface toxicity. Sadly, it is inaccessible in the United States. Ganciclovir is a newer synthetic drug with even more broad-spectrum antiviral coverage. Along with treating HSV and also VZV keratitis, topical ganciclovir also is effective in treating keratitis triggered by CMV [78]. Ganciclovir has been shown to be equally as effective as acyclovir, while causing less eye toxicity. It likewise may be less most likely to promote medication resistance [78].

HEDS I additionally checked out adjuvant oral acyclovir as a therapy for HSV stromal keratitis. A total of 104 patients receiving both topical trifluridine and also corticosteroids were randomized to receive 200 mg oral acyclovir or placebo, to be taken 5 times daily for 10 weeks [79]. Although the private investigators discovered that oral acyclovir postponed therapy failure (from 62 days in the sugar pill team to 84 days in the acyclovir team), this result was not statistically significant ($P = 0.46$). Oral acyclovir did cause a statistically considerable enhancement in BSCVA at 6 months ($P = 0.04$), but the relevance of this result is difficult to figure out given that there was a fairly large distinction in baseline BSCVA between teams. Oral acyclovir has actually been shown to be effective against VZV keratitis, and the outcomes of HEDS I often are used similarly to its treatment.

Valacyclovir, a newer antiviral, is well endured, and also there is some proof that it could have better eye infiltration [80]. Furthermore, the treatment dosage for valacyclovir is 1 g 3 times daily, in contrast to acyclovir, which is 400 mg 5 times everyday (800 mg 5 times daily for VZV), which aids in patient compliance. Oral valganciclovir is the preferred treatment for CMV stromal

keratitis, but it has significant adverse effects, consisting of aplastic anemia, which need to be carefully kept track of [81].

Conclusion:

Management of keratitis continues to be a significant challenge worldwide, more so in low- and also middle-income nations with inadequate healthcare sources. Although the outcome of therapy has improved substantially, several patients remain to degrade despite the very best treatment that can be used. The ongoing emergence of strains of microbes that are resistant to an ever-expanding variety of antimicrobials presents an added obstacle. Further study pertaining to prevention of microbial keratitis and improving host resistance are 2 worthwhile goals to go after. Large-scale public education programs to alert those in danger of microbial keratitis, and also to motivate earlier discussion, ought to be undertaken. Paired with this, education of specialists, general physicians, and various other health workers, in addition to general ophthalmologists, will go a long way to ensuring correct diagnosis, ideal treatment and also prompt referral before comprehensive damage to the cornea happens. Several research studies have indicated that the very best means to stop corneal abscess in reduced- and also middle-income nations is to deal with corneal abrasions in the health care setting within 48 hrs of the injury. This could be embraced in any type of population and is cost-efficient for both health and wellness providers and also the patient.

Reference:

1. Whitcher JP, Srinivasan M, Upadhyay MP. Corneal blindness: a global perspective. *Bull World Health Organ.* 2001;79:214-221.
2. Pascolini D, Mariotti SP. Global estimates of visual impairment: 2010. *Br J Ophthalmol.* 2012;96:614-618.
3. World Health Organization. Causes of blindness and visual impairment. Available at: <http://www.who.int/blindness/causes/en>. Accessed December 7, 2016.
4. Gupta N, Tandon R, Gupta SK, et al. Burden of corneal blindness in India. *Indian J Community Med.* 2013;38: 198-206.
5. Gonzales CA, Srinivasan M, Whitcher JP, Smolin G. Incidence of corneal ulceration in Madurai district, South India. *Ophthalmic Epidemiol.* 1996;3:159-166.
6. Dart JK, Stapleton F, Minassian D. Contact lenses and other risk factors in microbial keratitis. *Lancet.* 1991;338:650-653.
7. Green M, Apel A, Stapleton F. Risk factors and causative organisms in microbial keratitis. *Cornea.* 2008;27:22-27.
8. Keay L, Stapleton F, Schein O. Epidemiology of contact lens related inflammation and microbial keratitis: a 20-year perspective. *Eye Contact Lens.* 2007;33(6 Pt 2):346-353. discussion 362-363.
9. Thylefors B. Epidemiological patterns of ocular trauma. *Aust N Z J Ophthalmol.* 1992;20:95-98.
10. Sheng XL, Li HP, Liu QX, et al. Prevalence and associated factors of corneal blindness in Ningxia in northwest China. *Int J Ophthalmol.* 2014;7:557-562.
11. Saha S, Banerjee D, Khetan A, Sengupta J. Epidemiological profile of fungal keratitis in urban population of West Bengal, India. *Oman J Ophthalmol.* 2009;2:114-118.
12. Nirmalan PK, Katz J, Tielsch JM, et al. Ocular trauma in a rural south Indian population: the Aravind Comprehensive Eye Survey. *Ophthalmology.* 2004;111:1778-1781.
13. Spencer, W. H. (1985) *Cornea*, Chapter 3. In: *Ophthalmic Pathology: An Atlas and Textbook*, Vol. 1, 3rd ed., W. B. Saunders Company, Philadelphia.
14. Spear, P. (1985) Glycoproteins specified by Herpes simplex virus. In: *The Herpes Viruses* (B. Roizman, ed.), Plenum, New York, Vol. 3, p. 315.

15. Liesegang, T. J. (1992) Biology and molecular aspects of Herpes simplex and varicella-zoster virus infections. *Ophthalmology* 99:781–799.
16. Liesegang, T. J. (1985) Corneal complications from Herpes zoster ophthalmicus. *Ophthalmology* 92:316–324.
17. Wilhelmus, K. R. (1997) Syphilitic interstitial keratitis. Chapter 10. In: *Cornea and External Disease: Clinical Diagnosis and Management* (Krachmer, J. H., Mannis, M. J., and Holland, E. J., eds.), Mosby-Year Book, Inc., St. Louis.
18. Patterson, A. (1966) Interstitial keratitis. *Br. J. Ophthalmol.* 50:612–613.
19. Allen, J. H. and Byers, J. L. (1960) The pathology of ocular leprosy: cornea. *Arch. Ophthalmol.* 64:80–84.
20. Sakla, A. A., Donnelly, J. J., Lok, J. B., Khatami, M., and Rockey, J. H. (1986) Punctate keratitis induced by subconjunctivally injected microfilariae of *Onchocerca lienalis*. *Arch. Ophthalmol.* 104:894–898.
21. Von Noorden, G. K. and Buck, A. A. (1968) Ocular Onchocerciasis. *Arch. Ophthalmol.* 80:26–34.
22. Cogan, D. S. (1945) Syndrome of nonsyphilitic interstitial keratitis and vestibuloauditory symptoms. *Arch. Ophthalmol.* 33:144–149.
23. Lucchese, N. and Tessler, H. (1981) Keratitis associated with chronic iridocyclitis. *Am. J. Ophthalmol.* 92:717–721.
24. Aasuri, M. K., Madhukar, R., Sharma, S., and Rao, G. N. (1999) Co-occurrence of pneumococcal keratitis and dacryocystitis. *Cornea* 18:273–276.
25. O'Brien, T. P. (1997) Bacterial keratitis, chapter 94. In: *Cornea and External Disease: Clinical Diagnosis and Management, Vol. II* (Krachmer, et al., eds), J. H. Mosby-Year Book, Inc., St. Louis.
26. Wilson, S. E., Bannan, R. A., McDonald, M. B., and Kaufman, H. E. (1990) Corneal trauma and infection caused by manipulation of the eyelashes after application of mascara. *Cornea* 9:181–182.
27. Marioneaux, S. J., Cohen, E. J., Arentsen, J. J., and Laibson, P. R. (1991) *Moraxella* keratitis. *Cornea* 10:21–24.
28. Choudhuri, K. K., Sharma, S., Garg, P., and Rao, G. N. (2000) Clinical and microbiological profile of *Bacillus* keratitis. *Cornea* 19:301–306.
29. Zaidman, G. W., Coudron, P., and Piro, J. (1990) *Listeria monocytogenes* keratitis. *Am. J. Ophthalmol.* 109:334–339.
30. Elliott, D. C. (1951) An interpretation of the ocular manifestations of leprosy. *Ann. NY Acad. Sci.* 54:84.
31. Pillat, A. (1930) Leprosy bacilli in the scraping from the diseased cornea in a leper and comments on keratitis punctata superficialis laprosa. *Arch. Ophthalmol.* 6:306.
32. Baum, J., Barza, M., Weinstein, P., Groden, J., and Aswad, M. (1988) Bilateral keratitis as a manifestation of Lyme disease. *Am. J. Ophthalmol.* 105:75–77

33. McLeod SD, Kolahdouz-Isfahani A, Rostamian K, et al. The role of smears, cultures, and antibiotic sensitivity testing in the management of suspected infectious keratitis. *Ophthalmology*. 1996;103:23-28.
34. Kim E, Chidambaram JD, Srinivasan M, et al. Prospective comparison of microbial culture and polymerase chain reaction in the diagnosis of corneal ulcer. *Am J Ophthalmol*. 2008;146:714-723, 723.e711.
35. Chang HY, Chodosh J. Diagnostic and therapeutic considerations in fungal keratitis. *Int Ophthalmol Clin*. 2011;51:33-42.
36. Badiee P, Nejabat M, Alborzi A, et al. Comparative study of Gram stain, potassium hydroxide smear, culture and nested PCR in the diagnosis of fungal keratitis. *Ophthalmic Res*. 2010;44:251-256.
37. Zhang W, Yang H, Jiang L, et al. Use of potassium hydroxide, Giemsa and calcofluor white staining techniques in the microscopic evaluation of corneal scrapings for diagnosis of fungal keratitis. *J Int Med Res*. 2010;38:1961-1967.
38. Gopinathan U, Sharma S, Garg P, Rao GN. Review of epidemiological features, microbiological diagnosis and treatment outcome of microbial keratitis: experience of over a decade. *Indian J Ophthalmol*. 2009;57:273-279.
39. American Academy of Ophthalmology Cornea/External Disease Panel. Preferred Practice Pattern Guidelines. Bacterial Keratitis. San Francisco, CA: American Academy of Ophthalmology; 2013. Available at: www.aao.org/ppp.
40. Darougar S, Wishart MS, Viswalingam ND. Epidemiological and clinical features of primary herpes simplex virus ocular infection. *Br J Ophthalmol*. 1985;69:2-6.
41. El-Aal AM, El Sayed M, Mohammed E, et al. Evaluation of herpes simplex detection in corneal scrapings by three molecular methods. *Curr Microbiol*. 2006;52:379-382.
42. Nielsen E, Heegaard S, Prause JU, et al. Fungal keratitis improving diagnostics by confocal microscopy. *Case Rep Ophthalmol*. 2013;4:303-310.
43. Avunduk AM, Beuerman RW, Varnell ED, Kaufman HE. Confocal microscopy of *Aspergillus fumigatus* keratitis. *Br J Ophthalmol*. 2003;87:409-410.
44. Das S, Samant M, Garg P, et al. Role of confocal microscopy in deep fungal keratitis. *Cornea*. 2009;28:11-13.
45. Kanavi MR, Javadi M, Yazdani S, Mirdehghanm S. Sensitivity and specificity of confocal scan in the diagnosis of infectious keratitis. *Cornea*. 2007;26:782-786.
46. Vaddavalli PK, Garg P, Sharma S, et al. Role of confocal microscopy in the diagnosis of fungal and *acanthamoeba* keratitis. *Ophthalmology*. 2011;118:29-35.
47. Konstantopoulos A, Kuo J, Anderson D, Hossain P. Assessment of the use of anterior segment optical coherence tomography in microbial keratitis. *Am J Ophthalmol*. 2008;146:534-542.
48. Martone G, Pichierrri P, Franceschini R, et al. In vivo confocal microscopy and anterior segment optical coherence tomography in a case of *alternaria* keratitis. *Cornea*. 2011;30:449-453.

49. Austin A, Schallhorn J, Geske M, et al. Empiric treatment of bacterial keratitis: an international survey of corneal specialists. *Br J Ophthalmol Open*. [Accepted for publication].
50. McDonald EM, Ram FS, Patel DV, McGhee CN. Topical antibiotics for the management of bacterial keratitis: an evidence-based review of high quality randomised controlled trials. *Br J Ophthalmol*. 2014;98:1470-1477.
51. Constantinou M, Daniell M, Snibson GR, et al. Clinical efficacy of moxifloxacin in the treatment of bacterial keratitis: a randomized clinical trial. *Ophthalmology*. 2007;114:1622-1629.
52. O'Brien TP, Maguire MG, Fink NE, et al. Efficacy of ofloxacin vs. cefazolin and tobramycin in the therapy for bacterial keratitis. Report from the Bacterial Keratitis Study Research Group. *Arch Ophthalmol*. 1995;113:1257-1265.
53. Hyndiuk RA, Eiferman RA, Caldwell DR, et al. Comparison of ciprofloxacin ophthalmic solution 0.3% to fortified tobramycin-cefazolin in treating bacterial corneal ulcers. Ciprofloxacin Bacterial Keratitis Study Group. *Ophthalmology*. 1996;103:1854-1863.
54. Acharya NR, Srinivasan M, Mascarenhas J, et al. The steroid controversy in bacterial keratitis. *Arch Ophthalmol*. 2009;127:1231.
55. Cohen EJ. The case against the use of steroids in the treatment of bacterial keratitis. *Arch Ophthalmol*. 2009;127: 103-104.
56. Hindman HB, Patel SB, Jun AS. Rationale for adjunctive topical corticosteroids in bacterial keratitis. *Arch Ophthalmol*. 2009;127:97-102.
57. Den S, Sotozono C, Kinoshita S, Ikeda T. Efficacy of early systemic betamethasone or cyclosporin A after corneal alkali injury via inflammatory cytokine reduction. *Acta Ophthalmol Scand*. 2004;82:195-199.
58. Yi K, Chung TY, Hyon JY, et al. Combined treatment with antioxidants and immunosuppressants on cytokine release by human peripheral blood mononuclear cells in chemically injured keratocyte reaction. *Mol Vis*. 2011;17:2665-2671.
59. Williams RN, Paterson CA. The influence of topical corticosteroid therapy upon polymorphonuclear leukocyte distribution, vascular integrity and ascorbate levels in endotoxin-induced inflammation of the rabbit eye. *Exp Eye Res*. 1987;44:191-198.
60. Chung JH, Kang YG, Kim HJ. Effect of 0.1% dexamethasone on epithelial healing in experimental corneal alkali wounds: morphological changes during the repair process. *Graefes Arch Clin Exp Ophthalmol*. 1998;236: 537-545.
61. Tomas-Barberan S, Fagerholm P. Influence of topical treatment on epithelial wound healing and pain in the early postoperative period following photorefractive keratectomy. *Acta Ophthalmol Scand*. 1999;77:135-138.
62. Gritz DC, Kwitko S, Trousdale MD, et al. Recurrence of microbial keratitis concomitant with antiinflammatory treatment in an animal model. *Cornea*. 1992;11:404-408.
63. Gritz DC, Lee TY, Kwitko S, McDonnell PJ. Topical antiinflammatory agents in an animal model of microbial keratitis. *Arch Ophthalmol*. 1990;108:1001-1005.

64. Herretes S, Wang X, Reyes JM. Topical corticosteroids as adjunctive therapy for bacterial keratitis. *Cochrane Database Syst Rev*. 2014;CD005430.
65. Blair J, Hodge W, Al-Ghamdi S, et al. Comparison of antibiotic-only and antibiotic-steroid combination treatment in corneal ulcer patients: double-blinded randomized clinical trial. *Can J Ophthalmol*. 2011;46:40-45.
66. Carmichael TR, Gelfand Y, Welsh NH. Topical steroids in the treatment of central and paracentral corneal ulcers. *Br J Ophthalmol*. 1990;74:528-531.
67. Srinivasan M, Lalitha P, Mahalakshmi R, et al. Corticosteroids for bacterial corneal ulcers. *Br J Ophthalmol*. 2009;93: 198-202.
68. Gopinathan U, Garg P, Fernandes M, et al. The epidemiological features and laboratory results of fungal keratitis: a 10-year review at a referral eye care center in South India. *Cornea*. 2002;21:555-559.
69. O'Day DM, Head WS, Robinson RD, Clanton JA. Corneal penetration of topical amphotericin B and natamycin. *Curr Eye Res*. 1986;5:877-882.
70. Hariprasad SM, Mieler WF, Lin TK, et al. Voriconazole in the treatment of fungal eye infections: a review of current literature. *Br J Ophthalmol*. 2008;92:871-878.
71. Walsh TJ, Pappas P, Winston DJ, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. *N Engl J Med*. 2002;346:225-234.
72. Farooq AV, Shukla D. Herpes simplex epithelial and stromal keratitis: an epidemiologic update. *Surv Ophthalmol*. 2012;57:448-462.
73. Liesegang TJ, Melton 3rd LJ, Daly PJ, Ilstrup DM. Epidemiology of ocular herpes simplex. Incidence in Rochester, Minn, 1950 through 1982. *Arch Ophthalmol*. 1989;107: 1155-1159.
74. Reynaud C, Rousseau A, Kaswin G, et al. Persistent impairment of quality of life in patients with herpes simplex keratitis. *Ophthalmology*. 2017;124:160-169.
75. Morfin F, Thouvenot D. Herpes simplex virus resistance to antiviral drugs. *J Clin Virol*. 2003;26:29-37.
76. Tsatsos M, MacGregor C, Athanasiadis I, et al. Herpes simplex virus keratitis: an update of the pathogenesis and current treatment with oral and topical antiviral agents. *Clin Exp Ophthalmol*. 2016;44:824-837.
77. Chou TY, Hong BY. Ganciclovir ophthalmic gel 0.15% for the treatment of acute herpetic keratitis: background, effectiveness, tolerability, safety, and future applications. *Ther Clin Risk Manag*. 2014;10:665-681.
78. Colin J, Hoh HB, Easty DL, et al. Ganciclovir ophthalmic gel (Virgan; 0.15%) in the treatment of herpes simplex keratitis. *Cornea*. 1997;16:393-399.
79. Barron BA, Gee L, Hauck WW, et al. Herpetic Eye Disease Study. A controlled trial of oral acyclovir for herpes simplex stromal keratitis. *Ophthalmology*. 1994;101:1871-1882.
80. Goldblum D, Bachmann C, Tappeiner C, et al. Comparison of oral antiviral therapy with valacyclovir or acyclovir after penetrating keratoplasty for herpetic keratitis. *Br J Ophthalmol*. 2008;92:1201-1205.

81. Razonable RR. Antiviral drugs for viruses other than human immunodeficiency virus. Mayo Clin Proc. 2011;86: 1009-1026.

IJSER